-
Mashup Score: 1
It is not known how frequently a kidney biopsy specimen reveals monoclonal gammopathy (MG) of renal significance (MGRS) in patients with MG or what factors predict this finding. In a review of medical records of 6300 patients with MG, the authors found that only 160 (2.5%) had a biopsy. Of those, 96 (60%) had lesions unrelated to MG, with arteriosclerosis and diabetic nephropathy accounting for…
Source: American Society of NephrologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
It is not known how frequently a kidney biopsy specimen reveals monoclonal gammopathy (MG) of renal significance (MGRS) in patients with MG or what factors predict this finding. In a review of medical records of 6300 patients with MG, the authors found that only 160 (2.5%) had a biopsy. Of those, 96 (60%) had lesions unrelated to MG, with arteriosclerosis and diabetic nephropathy accounting for…
Source: American Society of NephrologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
It is not known how frequently a kidney biopsy specimen reveals monoclonal gammopathy (MG) of renal significance (MGRS) in patients with MG or what factors predict this finding. In a review of medical records of 6300 patients with MG, the authors found that only 160 (2.5%) had a biopsy. Of those, 96 (60%) had lesions unrelated to MG, with arteriosclerosis and diabetic nephropathy accounting for…
Source: American Society of NephrologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Rate & Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Pts w/ MGUS [August 2020] Klomjit, Leung @fervenzafernan1 @SethiRenalPath @LadanZand @JASN_News https://t.co/lSon6U9ARj #Nephpearls #NephTwitter #mmsm #onconeph #nephroonc https://t.co/Mkh4gaI5N7
-
-
Mashup Score: 0
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Correspondence from The New England Journal of Medicine — Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/Z8L2pkqNYT
-
-
Mashup Score: 0
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/sT1hmGfx1N
-
-
Mashup Score: 1
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy [Jun 23, 2020] Bridoux et al. JCO @ASCO_pubs https://t.co/O9uteG4QXh #mmsm #onconeph #nephroonc n=186 NDMM w/ AKI not on HD https://t.co/GUFZxGDjUr
-
Rate & Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Pts w/ MGUS [August 2020] Klomjit, Leung @fervenzafernan1 @SethiRenalPath @LadanZand @JASN_News https://t.co/zfuPySn5u9 #Nephpearls #NephTwitter #mmsm #onconeph #nephroonc